What You Should Know:
Rimidi, a clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, is announcing enhancements to its diabetes management platform, including the addition of Glycemic Risk Index (GRI) as an emerging tool for patient and population outcomes management.
The inclusion of CGM data and GRI into Rimidi’s platform and clinical workflows is made possible via an enhanced integration with Dexcom, a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes. Through the collaboration, glycemic control metrics will enable more proactive and personalized management of diabetes across populations to drive better care decisions.
Enhanced Metrics to Advance Care Management
Specifically, the Rimidi diabetes management platform will now include metrics for:
- Time in Range (TIR): The amount of time a patient spends in the target blood glucose range during a specified time period, often two weeks. For most patients, this is between 70 and 180 mg/dL, and is a measurement that leverages CGM data to see the number of times a patient’s blood glucose level has stayed in the target range vs. been high (hyperglycemia) or low (hypoglycemia). TIR is considered the gold standard of CGM data management and interpretation today. Rimidi presents the TIR for target glucose as well as additional categories of low, very low, high and very high glucose.
- Glycemic Risk Index: A new actionable metric for describing the quality of glycemia in CGM tracking, developed by the Diabetes Technology Society. This metric can be used to assess how well a patient is doing over time, manage a population and predict outcomes in intervention studies. The composite score is also thought to better correlate with the risk of complications and help identify areas for therapy adjustment. The use of GRI in clinical practice is just beginning to gain adoption.
“As continuous glucose monitoring (CGM) gains broader adoption and becomes standard of care in patients with Type 2 Diabetes and primary care, clinicians need strategies for effectively triaging their growing population of patients using CGM and identifying appropriate steps to improve glycemic control,” said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. “GRI is an exciting new tool in the toolkit for clinicians and Rimidi is committed to bringing this innovation into the clinical workflow.”